Dave Udit, Mosalakanti Jayanth, Guduri Pavan, Rumps Mia, Mulcahey Mary K
School of Medicine, Tulane University, New Orleans, LA, USA.
Department of Orthopaedic Surgery and Rehabilitation, Stritch School of Medicine - Loyola University Chicago, Maywood, IL, USA.
JSES Rev Rep Tech. 2024 Jun 17;4(4):715-719. doi: 10.1016/j.xrrt.2024.05.012. eCollection 2024 Nov.
A potential complication of distal biceps repair is heterotopic ossification (HO), which impacts both limb function and overall patient outcomes. Common HO prophylaxis methods include nonsteroidal anti-inflammatory drugs or localized radiation therapy. The purpose of this systematic review was to determine an effective means of providing HO prophylaxis following distal biceps repair.
A systematic review of the literature was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The following databases were searched for studies published after 1998: PubMed, Embase, and Cochrane Library. Studies were included if they compared patients who were placed on HO prophylaxis following distal biceps repair compared to those that were not placed on HO prophylaxis, were prospective randomized controlled trials or retrospective case-control studies, and evaluated HO prophylaxis regimens. Studies that were not written in English, analyzed animals or cadavers, and did not directly evaluate patients undergoing distal biceps repair, did not study HO rophylaxis, or had alternative study designs were excluded.
The initial search identified 134 studies, 4 of which met the inclusion criteria and were included in the study. Each of these 4 (100%) studies evaluated indomethacin, and 1 (25%) study evaluated both indomethacin and meloxicam. The included studies evaluated HO prophylaxis in the setting of both one- and two-incision distal biceps repairs. Overall, 2 of the 4 (50%) studies supported the use of indomethacin as HO prophylaxis, 1 of 4 (25%) did not support the use of indomethacin for HO prophylaxis, and 1 of 4 (25%) studies reported that indomethacin and meloxicam are similarly effective HO prophylaxis drugs. None of the studies meeting the inclusion criteria analyzed radiation therapy as a potential method for HO prophylaxis.
Indomethacin is commonly used as a prophylactic measure for HO following distal biceps repair; however, based on the results of this study, it is not necessary to use this routinely due to its limited efficacy in preventing HO and potential risks (eg, gastrointestinal upset, bleeding) associated with the medication. Future randomized studies should evaluate the use of other nonsteroidal anti-inflammatory drugs (eg, meloxicam) for HO prophylaxis in addition to not using any HO prophylaxis following either one- or two-incision distal biceps repairs.
肱二头肌远端修复的一个潜在并发症是异位骨化(HO),这会影响肢体功能和患者的整体预后。常见的HO预防方法包括非甾体类抗炎药或局部放射治疗。本系统评价的目的是确定肱二头肌远端修复后提供HO预防的有效方法。
根据系统评价和Meta分析的首选报告项目(PRISMA)指南对文献进行系统评价。检索了以下数据库中1998年后发表的研究:PubMed、Embase和Cochrane图书馆。纳入的研究需比较肱二头肌远端修复后接受HO预防的患者与未接受HO预防的患者,为前瞻性随机对照试验或回顾性病例对照研究,并评估HO预防方案。未用英文撰写、分析动物或尸体、未直接评估肱二头肌远端修复患者、未研究HO预防或有其他研究设计的研究被排除。
初步检索确定了134项研究,其中4项符合纳入标准并纳入研究。这4项研究(100%)均评估了吲哚美辛,1项研究(25%)同时评估了吲哚美辛和美洛昔康。纳入的研究在单切口和双切口肱二头肌远端修复的情况下评估了HO预防。总体而言,4项研究中有2项(50%)支持使用吲哚美辛作为HO预防措施,4项中有1项(25%)不支持使用吲哚美辛进行HO预防,4项研究中有1项(25%)报告吲哚美辛和美洛昔康是同样有效的HO预防药物。没有一项符合纳入标准的研究将放射治疗作为HO预防的潜在方法进行分析。
吲哚美辛通常用作肱二头肌远端修复后HO的预防措施;然而,根据本研究结果,由于其预防HO的效果有限以及与该药物相关的潜在风险(如胃肠道不适、出血),无需常规使用。未来的随机研究除了评估在单切口或双切口肱二头肌远端修复后不使用任何HO预防措施外,还应评估使用其他非甾体类抗炎药(如美洛昔康)进行HO预防的情况。